Another approach using tolerogenic DCs for the prevention/treatment of T1D is to use antisense oligonucleotides to downregulate costimulatory molecule expression (CD40, CD80, and CD86) in DCs [152]. This evidence concerns the gene CD80 and type 1 diabetes mellitus.